A New Case of Primary Signet Ring Cell Carcinoma of the Uterine Cervix: A Case Report and Review of the Literature

Doghri R1, Tounsi N2*, Slimane M2, Boujelbene N1, Driss M1, Charfi L1, Rahal K2 and Mrad K1

1Department of Pathology, Salah-Azaiez Institute, Boulevard Tunis, Tunisia
2Department of Surgery Carcinologique, Salah-Azaiez Institute, Boulevard Tunis, Tunisia

Abstract

Primary signet-ring cell carcinoma of cervix is extremely rare in the literature. Usually, Signet-Ring Cell Carcinomas (SRCCs) of the cervix are metastatic from a primary gastric, colonic, ovarian, or breast carcinoma. A 48-year-old woman was referred to our Department due to persistent abnormal vaginal bleeding during the last two months. Gynecologic examination revealed cervical tumor. Biopsy revealed a signet ring cell type of mucinous adenocarcinoma. Extensive systemic examination reveals liver metastases biopsy confirmed. The patient was treated with palliative chemotherapy. The prognosis of primary signet ring cell adenocarcinoma of the uterine cervix is still unclear because of the rare incidence of cases. In this report, we reviewed the literature to identify the clinical, pathological, and immunohistochemical features of this rare malignancy.

Keywords: Cervix neoplasms; Signet ring cell carcinoma; Immunohistochemical; Adenocarcinoma

Introduction

Carcinoma of the uterine cervix is the most common malignancy in female genital tract in developing countries [1]. The current frequency of cervical adenocarcinoma is 10% to 25% of all the cervical carcinomas in developed countries and most of them are endocervical type [1].

Mucinous adenocarcinoma of the cervix was subdivided into 5 subtypes: endocervical, intestinal, signet-ring cell, minimal deviation, and villoglandular [2]. Adenocarcinomas with signet ring cell are mostly metastatic from gastric, breast, colonic or ovarian carcinomas and primary tumor is extremely rare [1-3]. The prognosis of primary signet-ring cell carcinoma (PSRCCs) of the cervix is not well known as a result of the small number of case reports.

We describe a case of primary adenocarcinoma of the uterine cervix, signet-cell type. In addition, we reviewed all reported cases in the literature, to the best of our knowledge.

Case Report

A 48-year-old woman, gravida seven, para five, aborta 2, married at the age of 18 not yet menopause and her medical and family history was unremarkable. She was a heavy smoker (two pack/day) for 10 years, no alcohol, and used oral contraceptives on and off for about 10 years. She was admitted to our hospital for spontaneous and intermittent abnormal vaginal bleeding which had been present during the last two months. Gynecologic examination revealed diffuse enlargement of the cervix which had been replaced by an exophytic ulcerated, reddish lesion with distal parametrial infiltration. We performed a cervical biopsy and endocervical curettage. Microscopic examination shows cells with eccentric hyperchromatic nuclei and large mucin filled cytoplasmic vacuoles growing in clusters and in nests or columns within pools of extracellular mucin (signet-ring cells) (×400).

Immunohistochemical analysis showed positivity to p16 (× 200).

Figure 1: Microscopic examination shows cells with eccentric hyperchromatic nuclei and large mucin filled cytoplasmic vacuoles growing in clusters and in nests or columns within pools of extracellular mucin (signet-ring cells) (×400).

Figure 2: Immunohistochemical analysis showed positivity to p16 (× 200).

*Corresponding author: Tounsi N. Department of Surgery Carcinologique, Salah-Azaiez Institute, Boulevard of 9-Avril, 1001 Tunis, Tunisia, Tel:71563980; E-mail: Nesarine.tounsi@gmail.com

Received August 24, 2017; Accepted October 11, 2017; Published October 16, 2017


Copyright: © 2017 Doghri R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
total, oral endoscopy and mammography, failed to show any other primary tumor. We practiced an abdominal pelvic scanner which revealed lombo-aortic adenopathy as well as hepatic metastasis biopsy-confirmed. All these results were consistent with a primary PSRCC FIGO (2009) cervical tumor stage IVB. The patient was referred to medical oncology for palliative treatment. Cisplatin has been indicated at doses 50 mg/m² every 3 weeks. But, his health condition had severely and rapidly deteriorated, therefore she doesn’t receive chemotherapy. She was deceased three months later.

Discussion

The most common adenocarcinoma of the uterine cervix is the usual endocervical type [1]. Mucinous adenocarcinoma of signet-ring cell type is very rare [4,5]. Usually, signet-ring cell differentiation found in cervical carcinoma strongly suggests a metastatic carcinoma usually from a gastro-intestinal, appendicular, mammary or ovarian origin.

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>Age (yrs)</th>
<th>Presenting symptoms</th>
<th>FIGO stage</th>
<th>Immunohistochemical studies other than ER and PR</th>
<th>ER, PR</th>
<th>HPV</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moll et al. [9]</td>
<td>50</td>
<td>Post-coital vaginal bleeding, menometrorrhagia</td>
<td>III</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Rx, RT</td>
<td>DOD 10 mo</td>
</tr>
<tr>
<td>Mayorga et al. [6]</td>
<td>68</td>
<td>Post-coital bleeding</td>
<td>Ib</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Pre-chemo, Sx</td>
<td>NED 35 Mo</td>
</tr>
<tr>
<td>case (2)</td>
<td>74</td>
<td>Post-menopausal bleeding</td>
<td>Ib</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Sx</td>
<td>NED 25 Mo</td>
</tr>
<tr>
<td>Haswani et al. [5]</td>
<td>33</td>
<td>Post-coital vaginal bleeding</td>
<td>III</td>
<td>NA</td>
<td>ER: −</td>
<td>HPV type 18: +</td>
<td>Palliative RT and chemo</td>
<td>DOD 10 mo</td>
</tr>
<tr>
<td>Cardosi et al. [10]</td>
<td>53</td>
<td>Perimenopausal bleeding</td>
<td>Ib</td>
<td>NA</td>
<td>ER+ PR+</td>
<td>NA</td>
<td>Sx and RT</td>
<td>NED 18 Mo</td>
</tr>
<tr>
<td>Montani et al. [14]</td>
<td>29</td>
<td>Persistent abnormal genital Bleeding</td>
<td>III</td>
<td>Positive for CK, MUC5AC Negative for vimentin, MUC2, MUC6</td>
<td>ER: −, PR: −</td>
<td>−</td>
<td>Chemo</td>
<td>NED 6 Mo</td>
</tr>
<tr>
<td>Insabato et al. [8]</td>
<td>46</td>
<td>Vaginal bleeding in cervical polypoid lesion</td>
<td>Ib</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Sx, RT, Chemo</td>
<td>NED 8 Yrs</td>
</tr>
<tr>
<td>Suárez et al. [7]</td>
<td>80</td>
<td>Vaginal discharge</td>
<td>IIb</td>
<td>Positive for CK AE1-AE3, CK 20, CEA, chromogranin A, synaptophysin</td>
<td>NA</td>
<td>NA</td>
<td>Rx Chemo</td>
<td>DOD 18 Mo</td>
</tr>
<tr>
<td>Mc Cluggage et al. [17]</td>
<td>NA</td>
<td>Two cases</td>
<td>NA</td>
<td>Positive for CK 7 and CK 16</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>(2 cases)</td>
<td></td>
<td></td>
<td></td>
<td>Negative for CK 20 and CDX2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Versas et al. [13]</td>
<td>36</td>
<td>Thromboembolic events (Trousseau Syndrome)</td>
<td>IV</td>
<td>Positive for p16 and CK 7 Negative for CK 20, CDX2 and Dpc4.</td>
<td>ER: −, PR: −</td>
<td>+</td>
<td>Chemo</td>
<td>DOD 7 wks</td>
</tr>
<tr>
<td>Lowery et al. [15]</td>
<td>60</td>
<td>Post-menopausal bleeding</td>
<td>Ib1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>RT brachytherapy Sx</td>
<td>DOD&gt;10 years</td>
</tr>
</tbody>
</table>

Giordano et al. [4] 45 Vaginal discharge IIb Positive for CK 7, CA-125, CEA and p16 Negative for vinorelin, NA HPV type 18: + Sx NA 
O. Kaidar-Person [16] 37 post-coital bleeding IIb2 Negative for chromogranin , synaptosis, CEA. NA NA concomitant chemo radiotherapy Sx NED 4 mo 
Washimi et al. [11] 31 Abnormal vaginal bleeding. IIIa Negative for MUC1, MUC5AC, MUC6, p53, CK20, TTF-1, GCDFP-1, mammoglobin, chromogranin-1, p16, HIK1083. ER: -, PR: - HPV type 18: + Sx and chemo Disease-free at 41 mo 
Cracchiolo et al. [12] 64 Abdominal fullness. IVB Positive for MUC2, CDX2, CEA, CK7. ER: +, PR: + Cytokeratin 7, (CEA) P16 positive Palliative ± 3 mo 
Sar et al. [13] 48 Postcoital vaginal bleeding Ib Positive for p16, CDX-2, MUC1, MUC2 and MUC5AC. ER: -, PR: - HPV type 18: + Sx Disease-free at 18 mo 

Table 1: Previous reported cases of primary cervical carcinoma containing signet-ring cell morphology.

CKCK: Cytokeratin, MUC: Mucin; TTF: Thyroid Transcripton Factor; GCDFP: Gross Cystic Disease Fluid Protein; ER: Estrogen Receptor; PR: Progesteron Receptor; NA: Not Available; Sx: Surgery; Rx: Radiation Therapy; DOD: Died of Disease; NED: Not Evidence of Disease; Mo: Months; Yrs: Years; Wks: Weeks; Chemo: Chemotherapy; CEA: Carcinomembrinic Antigen; CDX-2: Caudal-Type Homebox 2; SMA: Smooth Muscle Actin; PGP: Protein Gene Product; TTF: Thyroid Transcripton Factor 1; Pre-Chemo: Preoperative Chemotherapy

To the best of our knowledge, only 20 cases (included our case) of primary cervical carcinoma containing signet-ring cell morphology have been reported in the literature (Table 1). In most cases of previous reports, the signet-ring cell component is included in a part of histological types [6]. All cases were admitted as primary only after a careful combined clinical, endoscopic and radiological investigation to rule out the presence of an occult primary site. Immunohistochemical and molecular studies have often provided important information for differential diagnosis. Several immunohistochemical markers have been used in the literature to support the primary origin of cervical cancer, although their usefulness is debatable. Indeed, primary cervical carcinoma can express colorectal antigens such as ACE, caudal-related homeobox (CDX-2) and cytokeratin 20 (CK20) [7,8]. Moreover, simultaneous positivity to ACE and keratin 7 do not differentiate between PCSRCC and gastric or mammary metastatic malignancy [5]. However, positivity for mammoglobin favors a mammary origin. No positive case of PCSRCC was reported [5]. Oestrogen and progesterone receptors have been tested in only 4 previous cases [2,3,9] and these were present only in one example [10]. Neuroendocrine differentiations have been demonstrated in two cases [7,10] but these markers were negative in our case. Positivity of Human Papillomavirus (HPV) DNA using molecular analysis provides diagnostic evidence of primary signet- ring cell carcinoma of the cervix [4,5]. The presence of HPV 18 has been determined in five cases of primary signet-ring cell carcinoma of the cervix [4,7,11-13]. No case was reported with negative p16 immunohistochemical staining [13]. In our case, as well as in some previous published examples of the PCSRCC, the primary cervical origin was supported by the presence of P16 Immunoreactivity [12,13], which may be considered a surrogate marker for HPV infection [4]. The absence of extra genital pathology, demonstrated by investigations at the moment of the diagnosis and later in the course of the disease, also supports this opinion [7]. The prognosis of primary signet-ring cell carcinoma of the cervix is not well known [1]. Ten patients had localized disease to the cervix and eight patients had advanced tumors [2,4,5,7,10-14], in one cases with stage IV, was expired shortly after 3 months [12]. However, extended survival in a low-stage tumor was reported in two cases [8,15]. We have not a clear consensus; the treatment of this rare tumor joins the treatment recommendations for uterine cervix adenocarcinoma [16]. A resistance to radiotherapy and/ or chemotherapy was reported [3-5,7,9], but it has been suggested that advanced stage disease is particularly aggressive [4,7,12,14].

Conclusion

Primary signet-ring cell carcinomas of the cervix are rare and associated with a poor outcome [17]. Prognosis seems to be related to the clinical stage [4,10]. Awareness of this entity is important as it simulate metastatic signet-ring cell carcinoma. Clinical investigations and immunohistological studies are essentials for differential diagnosis [4,8].

Competing Interests

The authors declare that they have no competing interests.

Ethical Approval

Our study did not require ethical form.

Consent

Written informed consent form was obtained from the patient for publication of this case report and images.

References


